Year |
Citation |
Score |
2019 |
Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Journal For Immunotherapy of Cancer. 7: 323. PMID 31771649 DOI: 10.1186/S40425-019-0811-X |
0.382 |
|
2019 |
Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorganic & Medicinal Chemistry Letters. 126640. PMID 31500996 DOI: 10.1016/J.Bmcl.2019.126640 |
0.359 |
|
2019 |
Zamler D, Yen E, Shingu T, Ren J, Kassab C, Liu J, Heimberger A, Hu J, Draetta G, Curran M. IMMU-10. ESTABLISHING EFFECTIVE MODELS FOR IMMUNOTHERAPY IN GBM Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.504 |
0.373 |
|
2015 |
Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America. 112: E5290-9. PMID 26351680 DOI: 10.1073/Pnas.1514418112 |
0.322 |
|
2015 |
Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology. 5: 117. PMID 26106583 DOI: 10.3389/Fonc.2015.00117 |
0.389 |
|
2013 |
Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology. 31: 3003-3003. DOI: 10.1200/Jco.2013.31.15_Suppl.3003 |
0.343 |
|
2013 |
Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O6 |
0.337 |
|
2012 |
Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/S13311-012-0144-7 |
0.4 |
|
2012 |
Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. Plos One. 7: e35222. PMID 22493742 DOI: 10.1371/Journal.Pone.0035222 |
0.325 |
|
2011 |
Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Plos One. 6: e19499. PMID 21559358 DOI: 10.1371/Journal.Pone.0019499 |
0.372 |
|
2010 |
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 4275-80. PMID 20160101 DOI: 10.1073/Pnas.0915174107 |
0.351 |
|
2009 |
Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Research. 69: 7747-55. PMID 19738077 DOI: 10.1158/0008-5472.Can-08-3289 |
0.358 |
|
2009 |
Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN. Immune rejection of mouse tumors expressing mutated self. Cancer Research. 69: 3545-53. PMID 19351857 DOI: 10.1158/0008-5472.Can-08-2779 |
0.372 |
|
2008 |
Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Pérez-Alvarez I, Ichii H, Mendez A, Ricordi C, Curran MA. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplantation. 17: 793-802. PMID 19044206 DOI: 10.3727/096368908786516828 |
0.434 |
|
2006 |
Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation. 116: 1935-45. PMID 16778987 DOI: 10.1172/Jci27745 |
0.361 |
|
2005 |
Shai E, Palmon A, Panet A, Marmary Y, Sherman Y, Curran MA, Galun E, Condiotti R. Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 137-43. PMID 15963929 DOI: 10.1016/J.Ymthe.2005.02.022 |
0.434 |
|
2005 |
Shai E, Condiotti R, Curran MA, Nolan GP, Galun E. 837. Prolonged Gene Expression in Murine Salivary Glands Following FIV-Based Lentiviral Vector Transduction Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.380 |
0.563 |
|
2004 |
Fenjves ES, Ochoa MS, Gay-Rabinstein C, Ricordi C, Curran MA. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. Cell Transplantation. 13: 489-96. PMID 15565861 DOI: 10.3727/000000004783983710 |
0.383 |
|
2004 |
Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochemical and Biophysical Research Communications. 320: 998-1006. PMID 15240147 DOI: 10.1016/J.Bbrc.2004.06.044 |
0.544 |
|
2004 |
Wolkowicz R, Nolan GP, Curran MA. Lentiviral vectors for the delivery of DNA into mammalian cells. Methods in Molecular Biology (Clifton, N.J.). 246: 391-411. PMID 14970606 DOI: 10.1385/1-59259-650-9:391 |
0.578 |
|
2002 |
Price MA, Case SS, Carbonaro DA, Yu XJ, Petersen D, Sabo KM, Curran MA, Engel BC, Margarian H, Abkowitz JL, Nolan GP, Kohn DB, Crooks GM. Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 645-52. PMID 12409263 DOI: 10.1016/S1525-0016(02)90725-2 |
0.576 |
|
2002 |
Curran MA, Ochoa MS, Molano RD, Pileggi A, Inverardi L, Kenyon NS, Nolan GP, Ricordi C, Fenjves ES. Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. Transplantation. 74: 299-306. PMID 12177606 DOI: 10.1097/00007890-200208150-00003 |
0.535 |
|
2002 |
Curran MA, Nolan GP. Recombinant feline immunodeficiency virus vectors. Preparation and use. Methods in Molecular Medicine. 69: 335-50. PMID 11987787 DOI: 10.1385/1-59259-141-8:335 |
0.511 |
|
2002 |
Curran MA, Nolan GP. Nonprimate lentiviral vectors. Current Topics in Microbiology and Immunology. 261: 75-105. PMID 11892254 DOI: 10.1007/978-3-642-56114-6_4 |
0.582 |
|
2000 |
Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 31-8. PMID 10933909 DOI: 10.1006/Mthe.1999.0007 |
0.582 |
|
Show low-probability matches. |